Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Taat Lifestyle & Wellness Ltd. C.TAAT

Alternate Symbol(s):  TOBAF

Taat is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in "Original", "Smooth", and "Menthol" varieties. Taat's base material is Beyond Tobacco™, a proprietary blend which undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with "Big Tobacco" pedigree, Taat is launching in the United States in Q4 2020 as the Company seeks to position itself in the $814 billion global tobacco industry.


CSE:TAAT - Post by User

Post by synectixon Jul 20, 2022 5:03pm
99 Views
Post# 34838428

FDA completely overwhelmed.....

FDA completely overwhelmed.....This will undoubtedly impact TAAT getting new products to market in a "reasonable" timeframe.

https://www.ctvnews.ca/health/fda-weighs-oversight-changes-after-formula-juul-troubles-1.5994170

Parents and politicians also have expressed frustration over the agency's handling of a recent decision to ban all e-cigarettes from Juul, the leading U.S. vaping company. A federal court quickly blocked the agency's order. FDA then backtracked further in court, saying it needed more time to review Juul's application due to its “unique scientific issues.”

The FDA has also struggled to review millions of other applications from vaping companies, prompting multiple missed regulatory deadlines over the last two years.

Califf again cited funding challenges, pointing out that the FDA cannot collect user fees from vaping companies to review their products. The agency has asked Congress for that authority.

“I don't think anyone anticipated that there would be 6.7 million vaping product applications that came rolling in during a pandemic that was stressing the entire agency,” Califf said.


<< Previous
Bullboard Posts
Next >>